New era in Alzheimer's disease therapeutics:transitioning from symptomatic management to disease-modifying paradigms
CHEN Xiao-chun
LIAO Jiang-feng
Abstract：The management of Alzheimer's disease(AD)is transitioning from symptomatic management to disease-modifying therapy(DMT).Conventional pharmacologic treatments provide only symptomatic relief and do not alter disease progression.Anti-amyloid β-protein(Aβ)monoclonal antibody drugs,exemplified by Lecanemab and Donanemab,have demonstrated efficacy in slowing cognitive decline in patients with early Alzheimer's disease.Improved access through insurance coverage and optimized dosing regimens has enhanced treatments availability;however,their use remains restricted to well-defined populations,mandating rigorous biomarker-based patient selection,and ongoing safety surveillance.Recent years have witnessed rapid advances in novel agents targeting tau pathology and neuroinflammation,as well as in technologies designed to enhance blood-brain barrier(BBB)penetration.Non-pharmacological interventions and immune cell-based therapies also show promising synergistic effects.Looking ahead,future strategies should focus on earlier intervention,promotion of precision medicine and combination therapies,and integration of multimodal approaches to transform Alzheimer's disease into a preventable and manageable disorder.
Keywords：Alzheimer diseasePrecision medicineBiomarkersReview
Publication Date：2026-02-25
Online Publishing Date：2026-04-07(First online date of this platform, not the publication date of the document)
Pages：3( 109-111 )